US-based cancer treatment data provider Syapse has secured $30m from investors including investment vehicles for pharmaceutical firms Amgen, Roche and Merck & Co, and care providers Ascension and Intermountain Healthcare.
Amgen Ventures, Ascension Ventures, Intermountain Ventures, Merck Global Health Innovation Fund and Roche Finance joined investment partnership Revelation Partners, which led the round through subsidiary Revelation Alpine, Safeguard Scientifics and Social Capital.
Founded in 2008, Syapse operates a network of healthcare data supported by a range of partners in the medical and healthcare space that supports and informs precision cancer care in addition to drug development, patient matching for clinical trials and monitoring of approved treatments.
Zack Scott, managing partner at Revelation Alpine, will take a seat on Syapse’s board of directors in conjunction with the round, which lifted the company’s overall funding to $69.5m.
Ascension Ventures led the company’s last round, a $25m series C in 2017 that also featured existing investors Social Capital and Safeguard Scientifics.
Ken Tarkoff, Syapse’s CEO, said: “We are incredibly proud of the partnerships we have developed and are grateful for the support of our industry-leading investors who share in our vision of tapping into the power of real-world data to accelerate the development and delivery of innovative new cancer therapies.”
